Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

SMILE vs advanced surface ablation in low myopia

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Keratorefractive Results II

Venue: Poster Village: Pod 2

First Author: : S.Taneri GERMANY

Co Author(s): :    S. Kiessler   A. Rost   T. Schultz   M. Elling   B. Dick  

Abstract Details

Purpose:

To compare the visual and refractive outcomes of SMILE and Advanced Surface Ablation (ASA) for low myopia and myopic astigmatism.

Setting:

Center for Refractive Surgery, Eye Department at St. Francis Hospital, Muenster, Germany

Methods:

Observational case series of 123 consecutive SMILE and 29 consecutive ASA for low myopia. Inclusion criteria: preoperative spherical equivalent up to -3.5 D, astigmatism up to 1.5 D, and corrected distance visual acuity (CDVA) of 1.0 (decimal scale) or better. Same surgeon performed SMILE with the VISUMAX 500 Hz femtosecond laser (Zeiss, Oberkochen, Germany) and ASA with the Technolas 217P excimer laser (Bausch & Lomb Technolas, Munich, Germany). Outcome analysis: uncorrected distance visual acuity (UDVA, decimal scale), CDVA (decimal scale), subjective refraction, and objective refraction according to the Standard Graphs for Reporting Refractive Surgery, and also including efficacy index.

Results:

Mean UDVA was 0.78/0.98/1.25 after SMILE and 0.32/0.57/1.07 after surface ablation at day 1/1 week/3 months, respectively. Mean efficacy index was 0.58/0.71/0.91 after SMILE and 0.26/0.47/0.84 after surface ablation at day 1/1 week/3 months, respectively. UDVA after 3 months was same or better than preop CDVA in 65% of SMILE eyes and 48% of ASA eyes. At 3 months, mean UDVA after SMILE was 0,99 (ASA: 0.95). At 3 months 93% of SMILE eyes were +/- 0.5 D of spherical equivalent (ASA: 88 %).

Conclusions:

SMILE for low myopia was found to be safe and effective with outcomes similar or better to those obtained with ASA.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous